| Primary |
| Product Used For Unknown Indication |
20.0% |
| Bone Marrow Conditioning Regimen |
14.2% |
| Prophylaxis |
13.3% |
| Aplastic Anaemia |
10.6% |
| Infection Prophylaxis |
7.5% |
| Prophylaxis Against Graft Versus Host Disease |
6.6% |
| Immunosuppression |
3.8% |
| Renal Transplant |
3.7% |
| Premedication |
3.4% |
| Prophylaxis Against Transplant Rejection |
2.9% |
| Antiviral Prophylaxis |
2.1% |
| Antifungal Prophylaxis |
2.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.8% |
| Acute Graft Versus Host Disease |
1.7% |
| Acute Myeloid Leukaemia |
1.4% |
| Hypertension |
1.4% |
| Immunosuppressant Drug Therapy |
1.2% |
| Constipation |
1.0% |
| Graft Versus Host Disease |
0.8% |
| Insomnia |
0.8% |
|
| Pyrexia |
15.1% |
| Post Transplant Lymphoproliferative Disorder |
13.5% |
| Vomiting |
7.9% |
| Transplant Rejection |
7.1% |
| Therapeutic Response Decreased |
5.6% |
| Urinary Tract Infection |
4.8% |
| Respiratory Failure |
4.0% |
| Sepsis |
4.0% |
| Serum Sickness |
4.0% |
| Staphylococcal Sepsis |
4.0% |
| Thrombocytopenia |
4.0% |
| Hypersensitivity |
3.2% |
| Kidney Transplant Rejection |
3.2% |
| Rash |
3.2% |
| Renal Failure |
3.2% |
| Transplant Failure |
3.2% |
| White Blood Cell Count Decreased |
3.2% |
| Death |
2.4% |
| Drug Ineffective |
2.4% |
| Drug Ineffective For Unapproved Indication |
2.4% |
|
| Secondary |
| Product Used For Unknown Indication |
23.2% |
| Bone Marrow Conditioning Regimen |
18.3% |
| Infection Prophylaxis |
9.8% |
| Prophylaxis Against Graft Versus Host Disease |
9.4% |
| Acute Myeloid Leukaemia |
5.9% |
| Acute Graft Versus Host Disease |
4.5% |
| Prophylaxis |
4.3% |
| Renal Transplant |
4.2% |
| Aplastic Anaemia |
3.7% |
| Premedication |
3.4% |
| Graft Versus Host Disease |
2.3% |
| Kidney Transplant Rejection |
2.0% |
| Immunosuppression |
1.9% |
| Skin Graft |
1.4% |
| Transplant Rejection |
1.2% |
| Hypertension |
1.1% |
| Prophylaxis Against Transplant Rejection |
1.1% |
| Haematological Malignancy |
1.0% |
| Immunosuppressant Drug Therapy |
0.8% |
| Liver Disorder |
0.7% |
|
| Pyrexia |
14.0% |
| Hypersensitivity |
10.5% |
| Vomiting |
8.1% |
| Thrombocytopenia |
7.0% |
| Inflammation |
5.8% |
| Sepsis |
5.8% |
| Transplant Rejection |
5.8% |
| Bronchopulmonary Aspergillosis |
4.7% |
| Infusion Site Infection |
4.7% |
| Venoocclusive Disease |
4.7% |
| White Blood Cell Count Decreased |
4.7% |
| Graft Versus Host Disease |
3.5% |
| Liver Abscess |
3.5% |
| Renal Failure |
3.5% |
| Acute Prerenal Failure |
2.3% |
| Clostridium Difficile Colitis |
2.3% |
| Drug Ineffective For Unapproved Indication |
2.3% |
| Encephalitis |
2.3% |
| Hepatitis |
2.3% |
| Hepatotoxicity |
2.3% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
11.7% |
| Product Used For Unknown Indication |
11.0% |
| Peripheral T-cell Lymphoma Unspecified |
9.7% |
| Prophylaxis Against Renal Transplant Rejection |
7.8% |
| Aplastic Anaemia |
6.5% |
| Stem Cell Transplant |
6.5% |
| Bone Marrow Conditioning Regimen |
5.2% |
| Renal Transplant |
5.2% |
| Prophylaxis |
4.5% |
| Prophylaxis Against Transplant Rejection |
4.5% |
| Antifungal Prophylaxis |
3.9% |
| Blood Pressure Decreased |
3.9% |
| Antiviral Prophylaxis |
3.2% |
| Hypertension |
3.2% |
| Cellulitis |
2.6% |
| Immunosuppression |
2.6% |
| Bone Marrow Transplant Rejection |
1.9% |
| Graft Versus Host Disease |
1.9% |
| Immunosuppressant Drug Therapy |
1.9% |
| Infection |
1.9% |
|
| Soft Tissue Inflammation |
13.0% |
| Zygomycosis |
8.7% |
| Anaemia |
4.3% |
| Diabetic Foot |
4.3% |
| Drug Level Fluctuating |
4.3% |
| Endometrial Cancer Metastatic |
4.3% |
| Engraft Failure |
4.3% |
| Gastritis |
4.3% |
| Haemolysis |
4.3% |
| Hot Flush |
4.3% |
| Myocarditis |
4.3% |
| Papilloedema |
4.3% |
| Peripheral Sensorimotor Neuropathy |
4.3% |
| Rash |
4.3% |
| Renal Tubular Necrosis |
4.3% |
| Respiratory Syncytial Virus Infection |
4.3% |
| Sepsis |
4.3% |
| Subarachnoid Haemorrhage |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Toxicity To Various Agents |
4.3% |
|
